
The SD, GPTL is responsible for providing strategic direction and leading the global drug development with one late stage asset that can have multiple indications in development, (or two early assets in different indications).
As the accountable program(s) owner, the GPTL, leads and chairs the Global Project Team (GPT), which determines the overall strategy for the asset/s across indications.
The GPT is responsible for creating an integrated development plan for each indication and overseeing the program. The GPTL is the “one voice” for the GPT up the line (R&D Leadership, Development Steering Committee and Executive Steering Committee). The GPT role is one of leadership, being proactive and interactive, and emphasizing partnership with all GPT members and Project Sub teams, functional heads and consultants both within, and outside R&D. The GPTL should stimulate creative and productive discussion, motivate, ownership and urgency (when necessary) as well as robust discussions of risk identification and mitigation opportunities, and ensure clarity of purpose and responsibilities with the GPT. The GPTL has the negotiation and persuasion skills necessary to ensure the program's success and sets goals for the GDT and specific program-related goals for the Core Team members.
AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics.
We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorization and employment eligibility verification requirements.
Alexion is proud to be an Equal Employment Opportunity and Affirmative Action employer. We are committed to fostering a culture of belonging where every single person can belong because of their uniqueness. The Company will not make decisions about employment, training, compensation, promotion, and other terms and conditions of employment based on race, color, religion, creed or lack thereof, sex, sexual orientation, age, ancestry, national origin, ethnicity, citizenship status, marital status, pregnancy, (including childbirth, breastfeeding, or related medical conditions), parental status (including adoption or surrogacy), military status, protected veteran status, disability, medical condition, gender identity or expression, genetic information, mental illness or other characteristics protected by law.
The annual base pay for this position ranges from 206,993.60 - 310,490.40 USD Annual. Our positions offer eligibility for various incentives—an opportunity to receive short-term incentive bonuses, equity-based awards for salaried roles and commissions for sales roles. Benefits offered include qualified retirement programs, paid time off (i.e., vacation, holiday, and leaves), as well as health, dental, and vision coverage in accordance with the terms of the applicable plans.
30-Sept-2026
13-Oct-2026
Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.

Alexion, AstraZeneca Rare Disease is focused on pioneering new possibilities for the rare disease community. We are driven by a mission to change what it means to live with a rare disease.
A leader in rare disease for more than three decades and today continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities.
As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.
Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex biology of the complement system into novel medicines. Alexion pushes boundaries to accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts, Alexion has offices around the world and continues to expand its reach to benefit more people globally.
GL/NP/0116
GL/NP/0095
Community Guidelines: https://bit.ly/39x9gqy